Adero Partners LLC Acquires 156 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Adero Partners LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,642 shares of the biopharmaceutical company’s stock after buying an additional 156 shares during the period. Adero Partners LLC’s holdings in Gilead Sciences were worth $296,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC increased its holdings in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 216 shares during the period. Morton Brown Family Wealth LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $35,000. Whipplewood Advisors LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $35,000. Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $40,000. Finally, Lee Danner & Bass Inc. bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $41,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $110.83 on Tuesday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The firm has a 50-day moving average of $105.82 and a 200-day moving average of $102.45. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The company has a market cap of $137.86 billion, a P/E ratio of 299.54, a P/E/G ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the firm posted ($1.32) EPS. The firm’s quarterly revenue was down .3% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, April 25th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 target price on the stock. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider now directly owns 121,152 shares of the company’s stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares of the company’s stock, valued at $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock worth $4,630,310 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.